Reviva Pharmaceuticals adjusts exec compensation; CEO salary $565k, options at $1.80

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Dr. Bhat base salary to $565k; CFO Prabhu $330k; VP Bhat $340k, effective retroactive Jan 1, 2025.
2024 cash bonuses: Dr. Bhat $157,500; Mr. Prabhu $79,950; Ms. Bhat $77,500.
2025 bonus targets: 50% of base (CEO), 41% (CFO), 32% (VP), subject to Compensation Committee criteria.
Option grants at $1.80 strike: CEO 519k shares, CFO 194.25k, VP 181.5k; ~42% vested immediately, rest monthly through Dec 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.